The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - Pfizer
Travel, Accommodations, Expenses - Ipsen
Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
 
Othon Iliopoulos
Employment - Biogen (I)
Stock and Other Ownership Interests - Tetraphase Pharma
Honoraria - Merck
Consulting or Advisory Role - Merck
Patents, Royalties, Other Intellectual Property - Patent
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Ipsen; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Frede Donskov
Research Funding - Ipsen (Inst); MSD Oncology (Inst); Pfizer (Inst)
 
Vivek Narayan
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; Pfizer/EMD Serono; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck
 
Benjamin Louis Maughan
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Peleton; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Tobias Else
Consulting or Advisory Role - Corcept Therapeutics; HRA Pharma
Research Funding - Corcept Therapeutics; Strongbridge Bio
 
Jodi K. Maranchie
No Relationships to Disclose
 
Sarah J. Welsh
No Relationships to Disclose
 
Sanjay Thamake
Employment - Merck
Stock and Other Ownership Interests - Peloton Therapeutics
Travel, Accommodations, Expenses - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Eric Kristopher Park
Employment - Merck
Stock and Other Ownership Interests - Merck
 
W. Marston Linehan
No Relationships to Disclose
 
Ramaprasad Srinivasan
Research Funding - AstraZeneca (Inst); Calithera Biosciences (Inst); Peloton Therapeutics (Inst); Sanofi (Inst)
 
W. Kimryn Rathmell
Stock and Other Ownership Interests - Caribou Publishing (I); Sitryx (I)
Honoraria - Merck (I); pfizer (I)
Consulting or Advisory Role - Caribou Biosciences (I); Sitryx (I)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (I); Calithera Biosciences (Inst); Incyte (I); Kadmon (I); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Tempus (I)
Patents, Royalties, Other Intellectual Property - ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapy
Travel, Accommodations, Expenses - Caribou Publishing (I); Chinese Society for Immunology (I); Merck (I); Pfizer (I)